Press releases

InDex discontinues the development of cobitolimod

22 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the company changes the date for when the interim report for Q1 2024 will be published. The interim report will now be published on Friday April 26, 2024 instead of Tuesday May 7, 2024 as previously communicated.

8 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the evaluation of alternatives for the Company´s future, as communicated in a press release on February 26, 2024, has been finalized and presented to the Board according to plan.

April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail

April 5 2024 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Tuesday May 7, 2024 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).

March 26, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that CEO Jenny Sundqvist and CFO & Deputy CEO Johan Giléus will leave the company per September 26, 2024.

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that, in light of today’s separate press release, with the announcement that the development of cobitolimod is discontinued, the company is evaluating other alternatives to maximize shareholder value. Alternatives such as merger and reverse merger are weighed against company liquidation. InDex Pharmaceuticals will not proceed with development of any of its other compounds. 

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that the company will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results justifying continued development.

Full focus on closing phase III program

19 January, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million.